EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia



A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia



BJU International 91(1): 41-44, January



OBJECTIVE To compare the effects of the doxazosin gastrointestinal therapeutic system, extended-release (doxazosin-GITS) formulation, and tamsulosin, another alpha1-antagonist, on total International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) in treating patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS Data were analysed from a prospective, randomized, double-blind, crossover study of men aged 50-80 years with concomitant BPH and hypertension as inclusion criteria. Fifty-two men were treated in four phases: phase I, placebo run-in for 2 weeks; phase II, first study drug doxazosin-GITS or tamsulosin for 8 weeks; phase III, washout with placebo for 2 weeks; and phase IV, second study drug tamsulosin or doxazosin-GITS for 8 weeks. Doxazosin-GITS was started at 4 mg/day and tamsulosin at 0.4 mg/day, and then titrated to 8 mg/day and 0.8 mg/day, respectively, after 4 weeks of therapy if the increase in Qmax was <3 mL/s or the reduction in total IPSS was <30%. Efficacy assessments included the IPSS and Qmax. Changes in blood pressure were not analysed, as most patients were actually not hypertensive. Endpoint efficacy data were analysed using an analysis of covariance model, with terms for sequence, phase, patients and sequence within patients, in addition to the baseline as covariate. Forty-seven men were treated in both efficacy arms of the study and were evaluable for analysis. RESULTS Doxazosin-GITS and tamsulosin significantly relieved lower urinary tract symptoms and significantly increased Qmax from baseline (P = 0.001). Doxazosin-GITS produced significantly greater improvements than tamsulosin in total IPSS (P=0.019) and obstructive subscores (P= 0.004) at the last treatment visit. The difference between doxazosin-GITS and tamsulosin in improving Qmax approached significance in favour of the former (mean change from baseline 2.6 vs 1.7 mL/s, respectively; between-group difference P= 0.089). Both treatments were well tolerated. CONCLUSIONS Treatment with doxazosin-GITS was significantly more effective than tamsulosin in relieving lower urinary tract symptoms.

(PDF emailed within 0-6 h: $19.90)

Accession: 010091668

Download citation: RISBibTeXText

PMID: 12614248

DOI: 10.1046/j.1464-410x.2003.03077.x



Related references

A randomised, double-blind, crossover study of doxazosin GITS and tamsulosin in patients with benign prostatic hyperplasia. European Urology Supplements 1(1): 108, January, 2002

A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. International Journal of Clinical Practice 60(10): 1172-1177, 2006

A randomized double blind study assessing the optimal dosage of doxazosin in treating patients with benign prostatic hyperplasia. Journal of Urology 159(5 SUPPL ): 330, 1998

29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scandinavian Journal of Urology and Nephrology 28(1): 77-82, 1994

Urtica dioica for treatment of benign prostatic hyperplasia: A prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal Pharmacotherapy 5(4): 1-11, 2005

Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal PharmacoTherapy 5(4): 1-11, 2006

Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. International Journal of Clinical Practice 58(1): 6-10, 2004

A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia. Journal of Urology 162(5): 1629-1632, 1999

A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. Medical Science Monitor 22: 1895-1902, 2016

Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study. Journal of Urology 154(1): 110-115, 1995

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51(6): 901-906, 1998

Comparison ofMurraya koenigii– andTribulus terrestris–Based Oral Formulation Versus Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Men Aged 5 Years A Double-Blind, Double-Dummy, Randomized Controlled Trial. 2011

Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial. Clinical Therapeutics 33(12): 1943-1952, 2012

Re: Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial. Journal of Urology 188(4): 1236-1237, 2012